CoChat

Dual drug targeting to kill colon cancers

Corona, Silvia Paola, Walker, Francesca, Weinstock, Janet, Lessene, Guillaume, Faux, Maree, Burgess, Antony W. · 2022 · Cancer Medicine
Cited by 8

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Introduction: Colorectal cancer (CRC) is driven by a small set of oncogenic and tumour suppressor mutations. However, different combinations of mutations often lead to poor tumour responses to individual anticancer drugs. We have investigated the antiproliferative and in vitro cytotoxic activity of pair‐wise combinations of inhibitors which target specific signalling pathways in colon cancer cells. Objectives: To target specific signaling pathways pairwise with inhibitors in order to kill colon cancer cells. Methods: The effects of different concentrations of two inhibitors on the proliferation and viability of colon cancer cell lines were measured using cell titre glow and cytotoxic assays in 2D and 3D cell micro‐cultures. One successful drug combination was used to treat a colon cancer cell line growing as a xenograft in nude mice. Results: Colon cancer cells in non‐adherent cultures were killed more effectively by combinations of pyrvinium pamoate (a Wnt pathway inhibitor) and ABT263 (a pro‐apoptotic Bcl‐2 family inhibitor) or Ly29004 (a PI3kinase inhibitor). However, in a mouse xenograft model, the formulation and toxicity of the ABT737/PP combination prevent the use of these drugs for treatment of tumours. Fortunately, oral analogues of PP (pyrvinium phosphate, PPh) and ABT737(ABT263) have equivalent activity and can be used for treatment of mice carrying SW620 colorectal cancer xenografts. The PPh/ABT263 induced SW620 tumour cell apoptosis and reduced the rate of SW620 tumour growth. Conclusion: By combining a Wnt signaling inhibitor (pyrvinium phosphate) and a pro‐survival inhibitor (ABT263) colon cancer cells can be killed. Combinations of Wnt signalling inhibitors with an inhibitor of the Bcl pro‐survival protein family should be considered for the treatment of patients with precancerous colon adenomas or advanced colorectal cancers with APC mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.4641

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 47

  1. 10.14740/gr1239 · DOI · Paper page
  2. 10.1056/NEJMoa071834 · DOI · Paper page
  3. 10.1038/s41598-020-76756-1 · DOI
  4. 10.1038/s41598-019-51981-5 · DOI · Paper page
  5. 10.3892/ijo.2016.3337 · DOI · Paper page
  6. 10.1056/NEJMoa1513257 · DOI · Paper page
  7. 10.1371/journal.pone.0003951 · DOI · Paper page
  8. 10.1038/nature03579 · DOI · Paper page
  9. 10.1158/0008-5472.CAN-07-5836 · DOI · Paper page
  10. Coffey RJ, 1987, Transforming growth factor α and β expression in human colon cancer lines: implications for an autocrine model, Cancer Res, 47, 4590
  11. Coffey RJ, 1986, Production of transforming growth factors by human colon cancer lines, Cancer Res, 46, 1164
  12. 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
  13. 10.1042/BJ20121140 · DOI · Paper page
  14. 10.1091/mbc.E20-05-0321 · DOI
  15. 10.1002/ijc.24289 · DOI
  16. 10.1053/j.gastro.2007.10.008 · DOI · Paper page
  17. 10.1158/0008-5472.CAN-08-2088 · DOI · Paper page
  18. 10.1083/jcb.139.4.1017 · DOI · Paper page
  19. 10.1073/pnas.0809957105 · DOI · Paper page
  20. 10.3109/08941939.2011.636476 · DOI
  21. 10.1242/dev.083154 · DOI · Paper page
  22. 10.3390/molecules25184094 · DOI
  23. 10.1186/s12943-015-0326-0 · DOI
  24. 10.1002/pbc.22740 · DOI
  25. 10.1038/nm.3048 · DOI · Paper page
  26. 10.1016/j.amjms.2017.11.017 · DOI
  27. 10.1038/sj.cdd.4401962 · DOI · Paper page
  28. 10.1038/nm.4010 · DOI · Paper page
  29. 10.18632/aging.103177 · DOI · Paper page
  30. Li W, 2020, Wnt/β‐catenin signaling may induce senescence of chondrocytes in osteoarthritis, Exp Ther Med, 20, 2631
  31. 10.1128/MCB.06023-11 · DOI · Paper page
  32. 10.1016/j.bbrc.2017.04.110 · DOI
  33. 10.1016/j.molcel.2007.05.034 · DOI · Paper page
  34. 10.1038/s41467-018-08150-5 · DOI
  35. Heinemann V, 2020, FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per‐protocol analysis of FIRE‐3, a randomised clinical trial, Br J Cancer, 124, 1
  36. 10.21873/anticanres.13146 · DOI
  37. 10.3390/cancers11070978 · DOI · Paper page
  38. 10.1038/s41418-019-0391-9 · DOI
  39. 10.1016/S0021-9258(17)37680-9 · DOI · Paper page
  40. 10.3390/cancers12041009 · DOI · Paper page
  41. 10.1158/1078-0432.CCR-07-0362 · DOI
  42. 10.1158/0008-5472.CAN-19-1184 · DOI
  43. 10.1016/j.jss.2007.04.021 · DOI · Paper page
  44. 10.1038/s42003-021-02607-y · DOI
  45. 10.1111/j.1349-7006.2006.00348.x · DOI
  46. 10.1158/1078-0432.CCR-12-1740 · DOI · Paper page
  47. 10.1001/jama.2012.8780 · DOI · Paper page

Cited by

See all 8

Metadata

Authors
Corona, S. P., Walker, F., Weinstock, J., Lessene, G., Faux, M., & Burgess, A. W.
Affiliations
  • Structural Biology Division WEHI Parkville Australia
  • Department of Medical Biology University of Melbourne Parkville Australia
Venue
Cancer Medicine
Publisher
Wiley
Published
2022-03-17
Volume
11
Issue
13
Pages
2612-2626
ISSN
2045-7634
Cited by
8
References
6
Language
en
Funders
  • Walter and Eliza Hall Institute
  • National Health and Medical Research Council (Development Grant # 1017059, Program Grant # 487922)
  • Ludwig Institute for Cancer Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual drug targeting to kill colon cancers. https://app.cochat.ai/papers/10.1002/cam4.4641
The paper
Corona, S. P., Walker, F., Weinstock, J., Lessene, G., Faux, M., & Burgess, A. W. (2022). Dual drug targeting to kill colon cancers. Cancer Medicine. https://doi.org/10.1002/cam4.4641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.